Jean-Charles Soria
Ran the phase 1 unit that pioneered many targeted therapies, and led the FLAURA trial that made osimertinib first-line.
Jean-Charles Soria built Gustave Roussy's DITEP early-phase unit, led FLAURA (osimertinib first-line), and later served as Director General and as an industry R&D leader before returning to academic medicine.
| Title | Journal | Year |
|---|---|---|
| Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA) | NEJM | 2018 |
Pages like this
not linked directly; found by shared links- TrialLAURA
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonYuichiro Ohe
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib, Non-small-cell lung cancer.
- PersonHelena A. Yu
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonJohn V. Heymach
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonFabrice Barlesi
Shares Gustave Roussy, Non-small-cell lung cancer.
- IdeactDNA-guided dose holidays for lung cancer targeted therapy
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- TrialFLAURA2
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib, Non-small-cell lung cancer.
- ProductDacomitinib
Shares EGFR, Non-small-cell lung cancer.